Guggenheim Reiterates Buy on Aralez Pharma (ARLZ) Following Yosprala Approval

September 15, 2016 4:00 PM EDT
Get Alerts ARLZ Hot Sheet
Price: $4.22 +0.48%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade ARLZ Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Guggenheim reiterated a Buy rating and $12.00 price target on Aralez Pharmaceuticals (NASDAQ: ARLZ) following the approval of Yosprala and the recent acquisition of Zontivity. Yosprala will complement ARLZ's Fibricor, which is another CV drug that ARLZ already markets, and Zontivity, which ARLZ recently acquired.

Analyst Louise Chen commented, "Today's approval of Yosprala and the recent acquisition of Zontivity underscore our positive investment thesis. We continue to believe that there is upside to consensus expectations and this could come from: 1) ARLZ's approved products; 2) The company's pipeline; as well as 3) Business develop, which ARLZ has publicly stated will be focused on CV and Pain. We believe Yosprala could reach sales of $200MM+ by '22. Additionally, we think ARLZ will be a successful consolidator of assets with its strong balance sheet, experienced management team, and low tax rate."

For an analyst ratings summary and ratings history on Aralez Pharmaceuticals click here. For more ratings news on Aralez Pharmaceuticals click here.

Shares of Aralez Pharmaceuticals closed at $5.46 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Definitive Agreement, Louise Chen, Guggenheim

Add Your Comment